# EDGAR Filing Document

**Accession Number:** 0001446847
**File Stem:** 0001104659-26-026123
**Filing Date:** 2026-3
**Character Count:** 4626
**Document Hash:** dde10697055019073174d6a7c6192e87
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-026123.hdr.sgml**: 20260311

**ACCESSION NUMBER**: 0001104659-26-026123

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260310

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20260311

**DATE AS OF CHANGE**: 20260311

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IRONWOOD PHARMACEUTICALS INC
- **CENTRAL INDEX KEY:** 0001446847
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 043404176
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-34620
- **FILM NUMBER:** 26741519

**BUSINESS ADDRESS:**
- **STREET 1:** 100 SUMMER STREET, SUITE 2300
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110
- **BUSINESS PHONE:** 617-621-7722

**MAIL ADDRESS:**
- **STREET 1:** 100 SUMMER STREET, SUITE 2300
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02110

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**Current Report Pursuant to** 

**Section 13 or 15(d) of the** 

**Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported):

March 10, 2026

**IRONWOOD PHARMACEUTICALS, INC.**

*(Exact name of registrant as specified in its charter)*

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-34620** | **04-3404176** |
| *(State or other jurisdiction* |  | *(I.R.S. Employer* |
| *of incorporation)* | *(Commission File Number)* | *Identification Number)* |

---

---

| | |
|:---|:---|
| **100 Summer Street** **, Suite 2300** |  |
| **Boston** **, Massachusetts** | **02110** |
| *(Address of principal* |  |
| *executive offices)* | *(Zip code)* |

---

**(617) 621-7722**

 

*(Registrant's telephone number,*

*including area code)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which<br> registered |
| Class A common stock, $0.001 par value | IRWD | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 8.01 Other Events.**

On March 10, 2026, Ironwood Pharmaceuticals, Inc. (the "Company") notified Wells Fargo Bank, National Association, as administrative agent (in such capacity, the "Agent"), under the Credit Agreement, dated May 21, 2023, as amended by Amendment No. 1 to Credit Agreement, dated September 27, 2024 (the "Amended Credit Agreement," and collectively, the "Credit Agreement"), by and among the Company, as borrower, the Agent and the other agents, lenders and letter of credit issuers parties thereto, that the Company satisfied the liquidity conditions set forth in the definition of "Maturity Date" in the Credit Agreement. Accordingly, the maturity date for the revolving credit facility provided under the Credit Agreement remains December 31, 2028, subject to the other terms and conditions of the Credit Agreement.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Ironwood Pharmaceuticals, Inc.** | **Ironwood Pharmaceuticals, Inc.** |
| Dated: March 11, 2026 | By: | /s/ Gregory Martini |
|  |  | Name: Gregory Martini |
|  |  | Title: Senior Vice President, Chief Financial Officer |

---